One report shows the epigenetic control of DR4 expression [23] as exemplified by the finding that 5-aza-2′-deoxycytidine, a demethylating agent, can increase the surface expression of DR4 in TRAIL-resistant melanoma cell lines, conferring reversal of the resistance to TRAIL, and ectopic expression of DR4 in these cells also achieved the reversal of resistance. Here, TNFRSF10A is linked to melanoma.